MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaa1443

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021

Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19).

de Alencar Julio Cesar Garcia, Moreira Claudia de Lucena, Müller Alicia Dudy, Chaves Cleuber Esteves, Fukuhara Marina Akemi, da Silva Elizabeth Aparecida, Miyamoto Maria de Fátima Silva, Pinto Vanusa Barbosa, Bueno Cauê Gasparotto, Lazar Neto Felippe, Gomez Gomez Luz Marina, Menezes Maria Clara Saad, Marchini Julio Flavio Meirelles, Marino Lucas Oliveira, Brandão Neto Rodrigo Antônio, Souza Heraldo Possolo, COVID Register Group

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequently, impaired gas exchange. We hypothesized that N-acetylcysteine (NAC) administration could restore this redox homeostasis and suppress unfavorable evolution in patients with coronavirus disease 2019 (COVID-19).

METHODS

This was a double-blind, randomized, placebo-controlled, single-center trial conducted at the Emergency Department of Hospital das Clínicas, São Paulo, Brazil, to determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19. We enrolled 135 patients with severe COVID-19 (confirmed or suspected), with an oxyhemoglobin saturation <94% or respiratory rate >24 breaths/minute. Patients were randomized to receive NAC 21 g (~300 mg/kg) for 20 hours or dextrose 5%. The primary endpoint was the need for mechanical ventilation. Secondary endpoints were time of mechanical ventilation, admission to the intensive care unit (ICU), time in ICU, and mortality.

RESULTS

Baseline characteristics were similar between the 2 groups, with no significant differences in age, sex, comorbidities, medicines taken, and disease severity. Also, groups were similar in laboratory tests and chest computed tomography scan findings. Sixteen patients (23.9%) in the placebo group received endotracheal intubation and mechanical ventilation, compared with 14 patients (20.6%) in the NAC group (P = .675). No difference was observed in secondary endpoints.

CONCLUSIONS

Administration of NAC in high doses did not affect the evolution of severe COVID-19.

CLINICAL TRIALS REGISTRATION: Brazilian Registry of Clinical Trials (REBEC): U1111-1250-356 (http://www.ensaiosclinicos.gov.br/rg/RBR-8969zg/).

Для цитирования: de Alencar Julio Cesar Garcia, Moreira Claudia de Lucena, Müller Alicia Dudy, Chaves Cleuber Esteves, Fukuhara Marina Akemi, da Silva Elizabeth Aparecida, Miyamoto Maria de Fátima Silva, Pinto Vanusa Barbosa, Bueno Cauê Gasparotto, Lazar Neto Felippe, Gomez Gomez Luz Marina, Menezes Maria Clara Saad, Marchini Julio Flavio Meirelles, Marino Lucas Oliveira, Brandão Neto Rodrigo Antônio, Souza Heraldo Possolo, COVID Register Group. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19).. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021. DOI: 10.1093/cid/ciaa1443.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.